U.S., Dec. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07297667) titled 'GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours' on Dec. 09.
Brief Summary: This study is being done to answer the following questions:
* Is the new cell therapy, GCAR1, safe to use, and what effects does it have on cancer?
* What is the right dose of the treatment which could be used in future studies?
Study Start Date: Jan. 31, 2026
Study Type: INTERVENTIONAL
Condition:
Alveolar Soft Part Sarcoma
Renal Cell Carcinoma
Triple Negative Breast Cancer
Intervention:
DRUG: Fludarabine
40mg/m2 IV
DRUG: Cyclophosphamide
600mg/m2 IV
BIOLOGICAL: GCAR1
Assigned at enr...